Compare Merck & Co., Inc. (MRK) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Plby Group Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Merck & Co., Inc. is far larger — about 2971.7× Plby Group Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Plby Group Inc for 24 Days on average.
| MRK | PLBY | |
|---|---|---|
Market Cap | $351.28B | $118.21M |
Volume | 7,969,665 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $2.71 |
52-Week Low | $82.49 | $0.98 |
Typical Hold Time | 98 Days | 24 Days |
Enterprise Value | $398.04B | $263.80M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
PLBY trades at $0.9867, down 3.26% today, amid a bearish technical signal with selling pressure across moving averages. The company reported Q2 2026 EPS of $0.00173, beating expectations, and revenue of $121 million in 2025, with net losses narrowing to $12.67 million. Recent news highlights leadership appointments aimed at driving brand growth. Analyst consensus is 75% buy, but high debt and negative equity pose fundamental risks.
Outlook remains cautious due to persistent losses and leveraged balance sheet, though cost controls and licensing growth offer potential upside. Key risks include execution on profitability, competitive pressures, and sensitivity to consumer spending. Investors should weigh analyst optimism against structural financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
